Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis

George C M Siontis1, Raffaele Piccolo1, Fabien Praz1

  • 1Department of Cardiology, University Hospital Bern, Bern, Switzerland.

Abstract

Insights

Early generation sirolimus-eluting stents (SES) are the most effective treatment for small coronary artery stenoses, showing superior angiographic and clinical outcomes. Further trials are needed to evaluate new generation drug-eluting stents (DES).

Area of Science:

  • Cardiovascular Interventions
  • Interventional Cardiology
  • Coronary Artery Disease Management

Background:

  • Percutaneous coronary intervention (PCI) in small coronary arteries carries higher risks of lesion failure and restenosis.
  • Optimal PCI strategy for small vessels remains a critical clinical question.

Purpose of the Study:

  • To evaluate the most appropriate percutaneous coronary intervention (PCI) strategy for treating stenoses in small coronary arteries.
  • To compare the efficacy of different PCI modalities in this patient subgroup.

Main Methods:

  • A network meta-analysis synthesized data from 19 randomized trials involving 5,072 patients.
  • Interventions compared included early generation sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), drug-coated balloons (DCB), bare-metal stents (BMS), and balloon angioplasty (BA).
  • Primary endpoint was the percentage of diameter stenosis (%DS); secondary endpoint was target-lesion revascularization.

Main Results:

  • Early generation SES demonstrated the best angiographic outcomes, significantly reducing diameter stenosis compared to DCB (-18%).
  • SES also showed a significant reduction in target-lesion revascularization compared to PES, DCB, BMS, and balloon angioplasty.
  • No trials evaluated new generation drug-eluting stents (DES).

Conclusions:

  • Early generation SES provide the most favorable angiographic and clinical results for treating stenoses in small coronary arteries.
  • Future randomized trials should assess new generation DES against this established standard.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
373
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
512
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
405
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
391
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
567